The global Dementia Treatment Market was valued at USD 17.06 billion in 2023 and is projected to reach USD 33.54 billion by 2032, with the U.S. market expected to almost double to USD 10.50 billion by 2032. Growth is fueled by an aging population, increased clinical adoption of innovative therapies, and government initiatives.

The Alzheimer’s disease dementia segment dominated the market in 2023, accounting for 60.14% market share due to its prevalence. Cholinesterase inhibitors, the leading drug class with a 45.19% share, are clinically proven to enhance cognitive performance in mild to moderate cases of dementia.

North America led the dementia treatment market with a 38.12% share in 2023, while the Asia-Pacific region is expected to register the highest growth during the forecast period. Factors such as aging populations, increased awareness, and improved healthcare accessibility are driving growth in the Asia-Pacific region. The Dementia Treatment Market is expected to grow in emerging economies due to the rise in middle-class population and increasing healthcare costs. The report offers unique insights like patient journey mapping, therapy pipeline analysis, and regional reimbursement frameworks to help businesses make informed decisions in the market. For more details, visit https://www.snsinsider.com/reports/dementia-treatment-market-6780/. SNS Insider is a leading global market research agency providing valuable insights to clients through various research techniques like surveys, video talks, and focus groups. Contact [email protected] for customized research solutions.

Read more at Globe Newswire: Dementia Treatment Market Size to Surpass USD 33.54 Billion